Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma

Drug Profile

Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma

Alternative Names: ADA 308; ADA 409; Backup; Backup I; Backup II; MDA-308; MDA-409

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medeia Therapeutics
  • Developer Aranda Pharma; Tarrex Biopharma
  • Class Antineoplastics; Cytoprotectives; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Preclinical Parkinson's disease; Prostate cancer
  • Research Neurodegenerative disorders; Peripheral ischaemia

Most Recent Events

  • 24 Aug 2017 Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma is available for licensing as of 24 Aug 2017. www.arandapharma.com
  • 23 Aug 2017 Aranda Pharma has patent protection for androgen receptor targeting small molecules in USA and European Union
  • 24 Mar 2017 Early research in Peripheral ischaemia in Finland (unspecified route) (Aranda Pharma pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top